Kawasaki disease: 40 years after the original report

Current Rheumatology Reports

Volumn 9, Issue 4, 2007, Pages 336-341

  Gedalia, Abraham ^a  

^a CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYTOKINE; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHYLPREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ACRODYNIA; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ANEURYSM; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG PULSE THERAPY; ERYTHROCYTE SEDIMENTATION RATE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; OUTCOME ASSESSMENT; PATHOGENESIS; REVIEW; RISK FACTOR; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS INFECTION;

EID: 34547857447     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0053-7     Document Type: Review

References (50)

1. Taubert KA, Rowley AH, Shulman ST: Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991, 119:279-282.
2. Kawasaki T: Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes [in Japanese]. Arerugi 1967, 16:178-222.
3. Yanagawa H, Nakamura Y, Ojima T, et al.: Changes in epidemic patterns of Kawasaki disease in Japan. Pediatr Infect Dis J 1999, 18:64-66.
4. Holman RC, Belay ED, Clarke MJ, et al.: Kawasaki syndrome among American Indian and Alaska native children. Pediatr Infect Dis J 1999, 18:451-455.
5. Holman RC, Curns AT, Belay ED, et al.: Kawasaki syndrome hospitalizations in the United States. Pediatrics 2003, 112:495-501.
6. Mason WH, Takahashi M: Kawasaki syndrome. Clin Infect Dis 1999, 28:169-185.
7. Yanagawa H, Yashiro M, Nakamura Y, et al.: Nationwide surveillance of Kawasaki disease in Japan. Pediatr Infect Dis J 1995, 14:69-71.
8. Cohen BJ: Human parvovirus B19 infection in Kawasaki disease [letter]. Lancet 1994, 344:59.
9. Marchette NJ, Melish ME, Hicks R, et al.: Epstein-Barr virus and other herpes infections in Kawasaki syndrome. J Infect Dis 1990, 161:680-684.
10. Dominguez SR, Anderson MS, Glodé MP, et al.: Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki disease. J Infect Dis 2006, 194:1697-1701. A blinded case-control, retrospective study on human coronavirus NL63 in KD. Detected the virus at the same frequency in nasopharyngeal wash of children with KD and control subjects, which indicates no association with this virus.
11. Dajani AS, Taubert KA, Gerber MA, et al.: Diagnosis and therapy of Kawasaki disease in children. Circulation 1993, 87:1776-1780.
12. Abinum M, Cant AJ: Toxic shock syndrome toxin-secreting staphylococcus aureus in Kawasaki syndrome [letter]. Lancet 1994, 343:300.
13. Davis HD, Kirk V, Jadavji T, et al.: Simultaneous presentation of Kawasaki disease and toxic syndrome in an adolescent male. Pediatr Infect Dis J 1996, 15:1136-1137.
14. Meissner HC, Leung DY: Superantigens, conventional antigens and etiology of Kawasaki syndrome. Pediatric Infect Dis J 2000, 19:91-94.
15. Leung DY, Meissner HC, Fulton DR, et al.: Toxic shock syndrome toxin-secreting staphylococcus aureus in Kawasaki syndrome. Lancet 1993, 342:1385-1387.
16. Terai M, Miwa K, Williams T, et al.: The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis 1995, 172:558-561.
17. Rowley AH, Shulman ST: New developments in the search for etiologic agent of Kawasaki disease. Curr Opin Pediatr 2007, 19:71-74. A comprehensive summary of the search for etiologic agents responsible for KD.
18. Dajani AS, Taubert KA, Gerber MA, et al.: Diagnosis and therapy of Kawasaki disease in children. Circulation 1993, 87:1776-1780.
19. Takahashi K, Oharaseki T, Naoe S, et al.: Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 2005, 47:305-310.
20. Rowley AH, Shulman ST, Spike BT, et al.: Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001, 166:1334-1343.
21. Brown TJ, Crawford SE, Cornwall ML, et al.: CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysm in acute Kawasaki disease. J Infect Dis 2001, 184:940-943.
22. Gavin PJ, Crawford SE, Shulman ST, et al.: Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 2003, 23:576-581.
23. Senzaki H: The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Arch Dis Child 2006, 91:847-851.
24. Suzuki A, Miyagawa-Tomota S, Komatsu K, et al.: Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease. Pediatr Int 2004, 46:590-596.
25. Kawasaki T, Kosaki T, Okawa S, et al.: A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974, 54:271-276.
26. Morens D, O'Brien R: Kawasaki disease in the United States. J Infect Dis 1978, 137:91-93.
27. Newburger JW, Takahashi M, Gerber MA, et al.: Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004, 114:1708-1733. A comprehensive review of the recommendations for the initial evaluation, treatment in the acute phase, and long-term management of patients with KD. A result of a multidisciplinary committee of experts revision of the recent American Heart Association recommendations.
28. Freeman AF, Shulman ST: Kawasaki disease: Summary of the American Heart Association Guidelines. Am Fam Physicians 2006, 74:1141-1148. A review that provide a summary of the clinical diagnostic and treatment guidelines, given by a panel of experts on KD and published by the American Heart Association and the American Academy of Pediatrics.
29. Beiser AS, Takahasha M, Baker AL, et al.: A predictive instrument for coronary artery aneurysms in Kawasaki disease. Am J Cardiol 1998, 81:1116-1120.
30. Harada K: Indication for intravenous gammaglobulin treatment for Kawasaki disease. In Proceedings of the Fourth International Symposium on Kawasaki Disease. Edited by Takahasha M, Taubert K. Dallas, TX: American Heart Association; 1993:459-462.
31. Mori M, Imagawa T, Yasui K, et al.: Predictors of coronary artery lesions after intravenous gammaglobulin treatment in Kawasaki disease. J Pediatr 2000, 137:177-180.
32. Nakamura Y, Yashiro M, Uehara R, et al.: Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004, 46:33-38.
33. Fukunishi M, Kikkawa M, Hamana K, et al.: Prediction of non-responsiveness to intravenous high dose gammaglobulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000, 137:172-176.
34. Abuhammour WM, Hasan RA, Eljamal A, Asmar B: Kawasaki disease hospitalizations in a predominantly African-American population. Clin Pediatr 2005, 44:721-725.
35. Porcalla AR, Sable CA, Patel KM, et al.: The epidemiology of Kawasaki disease in an urban hospital: does African American race protect against coronary artery aneurysms?Pediatr Cardiol 2005, 26:775-781. An epidemiology retrospective study of KD patients in an urban hospital in a predominantly African American population, showing a protective nature of African American ethnicity against the development of CAA. Raises speculation about the role of genetics and its interaction with immunity in the pathogenesis of KD.
36. Marquez J, Gedalia O, Candia L, et al.: Kawasaki disease: Clinical spectrum of 88 patients in a high prevalence African American population. J Natl Med Assoc 2007, in press.
37. Newburger JW, Takahashi M, Beiser AS, et al.: A single intravenous infusion of gammaglobulin as compared with four infusions in treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324:1633-1639.
38. Sundel RP, Burns JC, Baker A, Beiser A: Gamma globulin retreatment in Kawasaki disease. J Pediatr 1993, 123:657-659.
39. Wright DA, Newburger JW, Baker A, Sundel RP: Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996, 128:146-149.
40. Kato H, Koike S, Yokoyama T: Kawasaki disease: Effect of treatment on coronary artery involvement. Pediatrics 1979, 3:175-179.
41. Kijima Y, Kamiya T, Suzuki A, et al.: A trial procedure to prevent aneurysm formation of the coronary artery by steroid pulse therapy in Kawasaki disease. Jap Circ J 1982, 46:1239-1242.
42. Nonaka Z, Maekawa K, Okabe T, et al.: Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. In Kawasaki disease. Proceedings of the 5th International Kawasaki disease Symposium. Edited by Kato H. Amsterdam: Elsevier Science BV; 1995:328-331.
43. Shinohara M, Sone K, Tomomasa T, Morikawa A: Corticosteroids in the treatment of acute phase of Kawasaki disease. J Pediatr 1999, 135:465-469.
44. Sundel RP, Baker AL, Fulton DR, Newburger JW: Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003, 142:611-616.
45. Inoue Y, Okada Y, Shinohara M, et al.: A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006, 149:336-341. A report of the multicenter, prospective, randomized trial from Japan of corticosteroids in primary therapy for KD. Showed that the combination therapy of IVIG and corticosteroids resulted in fewer CAA before 1 month, shorter duration of fever, and faster decrease of CRP, as compared to the IVIG alone.
46. Newburger JW, Sleeper LA, McCrindle BW, et al.: Randomized trial of pulsed corticosteroids therapy for primary for treatment of Kawasaki disease. N Engl J Med 2007, 356:663-675. Report of the randomized trial of pulsed corticosteroid therapy for primary treatment of KD. This US multicenter trial showed no superiority of adding a pulse of methylprednisolone to the conventional IVIG therapy.
47. Petty RE, Cassidy JT: Kawasaki disease. In Textbook of Pediatric Rheumatology, 4th edn. Edited bv Cassidy JT, Petty RE. Oxford: W.B. Saunders Company; 2001:580-594.
48. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS: Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004, 31:808-810.
49. Burns JC, Mason WH, Hauger SB, et al.: Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005, 146:662-667.
50. Kavey RE, Allada V, Daniels SR, et al.: Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006, 114:2710-2738. A scientific statement from the American Heart Association Expert Panel on KD and other high-risk pediatric conditions. Discusses new aspects in the epidemiology, pathogenesis, natural history, risk levels, and recommendations for children after KD.